©The Author(s) 2026.
World J Gastrointest Pharmacol Ther. Mar 5, 2026; 17(1): 112872
Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.112872
Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.112872
Table 2 Adverse events, n (%)
| Overall (n = 3397) | No stent (n = 1979) | Plastic (n = 984) | FCSEMS (n = 319) | UCSEMS (n = 154) | |
| PEP | 107 (3.1) | 47 (2.4) | 33 (3.4) | 25 (7.8) | 6 (3.9) |
| Mild | 57 | 30 | 14 | 11 | 3 |
| Moderate | 37 | 12 | 13 | 11 | 2 |
| Severe | 13 | 5 | 6 | 3 | 1 |
| Stent migration | 57 (1.7) | NA | 29 (2.9) | 27 (8.5) | 1 (0.1) |
| Proximal | 17 | 8 | 8 | 1 | |
| Distal | 40 | 21 | 19 | 0 | |
| Cholangitis | 66 (1.9) | 26 (1.3) | 18 (1.8) | 17 (5.3) | 9 (5.8) |
| Perforation | 9 (0.3) | 5 (0.3) | 2 (0.2) | 2 (0.6) | 0 (0) |
| Death | 4 (0.1) | 2 (0.1) | 2 (0.2) | 0 (0) | 0 (0) |
- Citation: Zhang LY, Tikhe D, Shrigiriwar A, Ermerak G, Lee HH, Sin L, Turner I, Edwards P, Abi-Hanna D, Hourigan L, Kostalas S, Bassan M. Fully covered metal biliary stents confer a higher risk of post-endoscopic retrograde cholangiopancreatography pancreatitis. World J Gastrointest Pharmacol Ther 2026; 17(1): 112872
- URL: https://www.wjgnet.com/2150-5349/full/v17/i1/112872.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v17.i1.112872